United States Patent and Trademark Office

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

Retrieved on: 
Tuesday, March 14, 2023
Research, Neurodegenerative disease, Therapy, PBT2, SAN, Patent, ATH, Patient, End-user license agreement, Alzheimer's Association, Disease, United States Patent and Trademark Office, AH, Dementia, Master, Multiple system atrophy, ASX, Atomic mass, Traffic barrier, Pharmaceutical industry, Alzheimer's disease, Alterity, Parkinsonism

MELBOURNE, Australia AND SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted. The patent, entitled “Compounds for and methods of treating diseases” (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.

Key Points: 
  • 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.
  • Alterity also announced a Licensing Agreement for the new patent and a sub-licensing agreement for PBT2 to Professor Colin Masters, M.D., A.O., to advance these compounds for the treatment of Alzheimer’s and related diseases.
  • Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 in Alzheimer’s disease (AD).
  • PBT2 is a low molecular weight drug candidate discovered by Alterity and is currently the Company’s product candidate for Alzheimer’s disease.

Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO

Retrieved on: 
Monday, March 13, 2023
Combined, Infection, United States Patent and Trademark Office, Immunity, Heart, MOP, Biotechnology, MPH, CTX, Therapy, Safety, Patent, Liver, Messenger, Kidney, Vaccine, Cancer

BOSTON, March 13, 2023 /PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent infectious diseases and treat cancer, today announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7, 2023.

Key Points: 
  • BOSTON, March 13, 2023 /PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent infectious diseases and treat cancer, today announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7, 2023.
  • This patent recognizes significant innovative research and development advances by Combined Therapeutics in the mRNA vaccine field and covers its vaccine compositions which include its proprietary mRNA MOPCTx (Multi-Organ Protection) technology to deliver viral or bacterial antigens in combination with a panel of molecular adjuvants.
  • CTx's MOP technology offers a flexible mRNA platform that can be engineered to meet specific vaccine needs and demands.
  • Additionally, when combined with a molecular adjuvant, the CTx mRNA platform enhances several critical vaccine immunogenicity parameters including extending the duration of immunity,  decreasing the needed vaccine dose and improving the protection of vulnerable populations.

Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, March 9, 2023
SIV, Vaccine, Cancer, HIV, Neoplasm, Trifluridine/tipiracil, United States Patent and Trademark Office, MOS, Clinical trial, NCI, 1836 U.S. Patent Office fire, KRAS, ESMO, Fungal infection, Infection, CRC, National Cancer Institute, Simian immunodeficiency virus, Conference, Collaboration, CROI, Research, NIAID, Patient, FDA, DNA, Circulating tumor DNA, RECIST, Patent, Gilead Sciences, OS, MRR, Regorafenib, Progression-free survival, Therapy, ChAdOx1, NSCLC, Messenger, Immunotherapy, CORAL, SLATE, Pharmaceutical industry, Cryptocurrency, Nature Medicine, Gritstone

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • -- In August 2022, interim results from the Phase 1/2 trial of GRANITE, Gritstone’s individualized neoantigen vaccine for solid tumor cancers, were published in Nature Medicine ( here ).
  • -- In August 2022, Gritstone reported 6-month neutralizing antibody data from the first two cohorts of its CORAL-BOOST trial.
  • -- In October 2022, Gritstone shared interim positive results from the ongoing Phase 1 CORAL-BOOST and CORAL-CEPI studies at a Company-sponsored webinar .
  • Collaboration, license, and grant revenues were $19.9 million for the year ended December 31, 2022, compared to $48.2 million for the prior year.

SMX Files Patent to Unlock Circular Economy Participation for Auto, Aerospace and Infrastructure Applications

Retrieved on: 
Thursday, March 9, 2023
Carbon, Patent, SMX, United States Patent and Trademark Office, Aluminium, Recycling, Transport, Cryptocurrency

NEW YORK, March 9, 2023 /PRNewswire/ -- SMX (Security Matters) Public Limited Company (NASDAQ: SMX) (NASDAQ: SMXWW) has filed a patent with the United States Patent and Trademark Office for an application that could meet the demand for visibility and accounting by some of the largest industrial consumers of aluminum alloy products and materials.

Key Points: 
  • SMX technology provides material-intensive industries a blockchain platform for full lifecycle accounting of materials enabled via molecular-level marking (U.S. application no.
  • The SMX platform introduces a method for accurately accounting of the material from origination through production and re-use.
  • A commercialized, scalable SMX platform is intended to provide aluminum supply chain accounting needs for a variety of manufacturing, transportation, construction and electrical applications.
  • SMX technologies present a flexible, industry-agnostic solution for identifying presence of recycled aluminum material in finished products for additional accounting of reuse of recycle of material.

Emmersion Announces Issuance of New U.S. Patent For Its Adaptive Language Learning Method

Retrieved on: 
Thursday, March 9, 2023
1836 U.S. Patent Office fire, United States Patent and Trademark Office, Patent, Artificial intelligence, Language, Cognitive computer, Cryptocurrency, Film industry

AMERICAN FORK, Utah, March 9, 2023 /PRNewswire/ -- Emmersion, the leader in certifying language ability through artificial intelligence and developer of the TrueNorth language assessment, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11488489 to the company, which covers its adaptive language learning method. Emmersion's patent remains in force until 2038, and will play a key role in the development of new solutions that accurately assess and improve language skills through personalization.

Key Points: 
  • AMERICAN FORK, Utah, March 9, 2023 /PRNewswire/ -- Emmersion , the leader in certifying language ability through artificial intelligence and developer of the TrueNorth language assessment , announced that the United States Patent and Trademark Office issued U.S. Patent No.
  • 11488489 to the company, which covers its adaptive language learning method.
  • Emmersion's patent remains in force until 2038, and will play a key role in the development of new solutions that accurately assess and improve language skills through personalization.

FineLine Technologies Awarded Patent for Innovative RFID Smart Mold Management Solution

Retrieved on: 
Wednesday, March 8, 2023
Table tennis rubber, Patent, United States Patent and Trademark Office, RFID, Radio-frequency identification, Finelines, Maintenance, Health, Tire manufacturing

ATLANTA, March 8, 2023 /PRNewswire-PRWeb/ -- FineLine Technologies, a leading provider of variable data tags, labels and specialized RFID solutions for tire and rubber manufacturing, automotive, healthcare and retail industries, announced today that it has been granted a new patent by the United States Patent and Trademark Office. US Patent No. 11,453,186 focuses on mold management, a critical process for the tire and rubber manufacturing industry.

Key Points: 
  • FineLine Technologies RFID Smart Mold Management Solution helps improve the overall quality of a tire, ensuring that manufacturers can deliver high-quality products to their customers
    ATLANTA, March 8, 2023 /PRNewswire-PRWeb/ -- FineLine Technologies , a leading provider of variable data tags, labels and specialized RFID solutions for tire and rubber manufacturing, automotive, healthcare and retail industries, announced today that it has been granted a new patent by the United States Patent and Trademark Office.
  • 11,453,186 focuses on mold management, a critical process for the tire and rubber manufacturing industry.
  • Proper mold management is crucial to the overall quality of a tire accounting for approximately 35 percent of the tire's quality.
  • "We are thrilled to be delivering and implementing this innovative RFID solution with several leading tire manufacturers," said George Hoffman, CEO of FineLine Technologies.

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, March 8, 2023
Orange Book, Chronic cough, Nalbuphine, Patent, Trevi, IPF, United States Patent and Trademark Office, Idiopathic pulmonary fibrosis, Therapy, Pharmaceutical industry, HAVEN

(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.

Key Points: 
  • (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.
  • Trevi expects the resulting patent will be Orange Book-listable with an anticipated expiration in 2039.
  • Trevi intends to continue to prosecute additional patent applications to further enhance its existing patent estate protecting nalbuphine ER across multiple chronic cough conditions as additional clinical data is generated.
  • "We are pleased with this allowance of claims to further secure IP protection for Haduvio through 2039 for the treatment of chronic cough in IPF," said Jennifer Good, President and CEO of Trevi Therapeutics.

Laguna Candles Celebrates 20 Years As Global Luxury Supplier Following Trademark Victory

Retrieved on: 
Tuesday, March 7, 2023
Family, Amazon, Goliath, Growth, United States Patent and Trademark Office, Magazine, Name, Entrepreneurship, Hendricks, Trademark, Love, Patent, Weeping Angel, Auction, New York (magazine), Allure

LAGUNA BEACH, Calif., March 7, 2023 /PRNewswire/ -- Twenty years ago, Laguna Candles opened for business, fueled by a love for the calming effects of beautiful home fragrance and a desire to be on the cutting edge of a growing consumer appetite for cleaner burning candles. Founded by Sharie Hendricks, the company had humble beginnings in her family's kitchen and garage, a hub for experimenting with various fragrances, wax blends, packaging and more. Before long, Laguna Candles emerged as a premiere Black and woman-owned business, now enjoyed globally at the finest luxury hotels, spas and specialty stores with thousands of hand-poured, bespoke candles sold around the country and beyond.

Key Points: 
  • The company has weathered storms, including intentional efforts from a sizeable retail company to diminish Laguna Candles' trademark rights.
  • Laguna Candles was victorious in United States trademark court and has been supported by retailers including Amazon to only sell the original Laguna Candles line.
  • "From the first day we opened Laguna Candles for business we have remained committed to our vision of luxury products with sustainable ingredients," Hendricks shares.
  • For more information about Laguna Candles, please visit http://www.lagunacandles.com/ follow @lagunacandles or send an email to [email protected]

NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform

Retrieved on: 
Tuesday, March 7, 2023
Depression, DSM-IV codes, Parkinson's disease, United States Patent and Trademark Office, Patent, Chronic pain, EDEN, Electrode, NMTC, Patient, Invention, Epilepsy, Temperature, On Formally Undecidable Propositions of Principia Mathematica and Related Systems, OCD, Pharmaceutical industry, Medical device

EDEN PRAIRIE, Minn., March 7, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology.

Key Points: 
  • The patent, titled "Improved Neural Depth Probes and Related Systems and Methods," adds to NeuroOne's intellectual property portfolio, and is focused on a layered thin film neural depth electrode.
  • The electrode could have potential applications in a wide variety of neurological procedures for both diagnostic and therapeutic use.
  • Dave Rosa, CEO of NeuroOne, comments, "NeuroOne is committed to protecting our groundbreaking electrode technology with respect to device claims and proprietary manufacturing processes.
  • We look forward to continued success with our patent applications."

U.S. Patent and Trademark Office Kicks Off National Tour to Help Underrepresented Entrepreneurs

Retrieved on: 
Tuesday, March 7, 2023
Under Secretary of Commerce for Intellectual Property, United States Patent and Trademark Office, Commerce, Ecosystem, Invention, Patent, Woman, Native Americans, University of Minnesota Crookston, Bank of America, Hispanic and Latino Americans, Intellectual property, World Intellectual Property Organization, African Americans, Management, University, Entrepreneurship, IAP, Organization, Bank, BETA, Pharmaceutical industry, Television

WASHINGTON, March 7, 2023 /PRNewswire/ -- The United States Patent and Trademark Office (USPTO) in an effort to provide assistance to under-resourced inventors and small businesses will kick off its national tour by hosting a two-day event in Minneapolis through its Patent Pro Bono Program. The free event, co-presented by the USPTO and the Patent Pro Bono Advisory Council a 501(c)(3), will focus on helping under-resourced inventors gather information on how to file patents, access funding and eventually create more jobs.

Key Points: 
  • WASHINGTON, March 7, 2023 /PRNewswire/ -- The United States Patent and Trademark Office (USPTO) in an effort to provide assistance to under-resourced inventors and small businesses will kick off its national tour by hosting a two-day event in Minneapolis through its Patent Pro Bono Program .
  • "Pro bono counsel serves as a valuable bridge to the innovation economy by providing critical assistance to underrepresented inventors.
  • The Minnesota program is facilitated through LegalCORPS, a nonprofit based in Minneapolis that provides free assistance in non-litigation business law matters to low-income inventors.
  • Inventors interested in attending the free seminar on the 9th can sign up for the morning session here and the afternoon session here .